TRIAL DETAIL
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay)
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay) |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Recruiting |
|||
Phase: |
1 |
Start Date 07/24/2019 |
Age of Trial (yrs) 4.2 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
SDH-directed |
|||
Strategy: |
Radio labeled tracer for GRPR expressing malignancies |
|||
Trial Type: |
Specifically GIST plus other cancers |
|||
Other Protocol IDs: |
CAAA603A12101 |
|||
Sponsor: |
Advanced Accelerator Applications |
|||
Patient Contact: |
Novartis Pharmaceuticals
1-888-669-6682
+41613241111
Novartis.email@novartis.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
| Advanced Acelerator Applications Pipeline |
| Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1500 E. Duarte Road |
Duarte |
CA |
91010 |
USA |
|
875 Blake Wilbur Drive |
Palo Alto |
CA |
94304 |
USA |
|
Baltimore |
MD |
21231 |
USA |
||
Portland |
OR |
97239 |
USA |
||
Innsbruck |
6020 |
Austria |
|||
's-Gravendijkwal 230 |
Rotterdam |
3015 |
Netherlands |
||
119-129 |
Barcelona |
08035 |
Spain |
||
Cambridge |
CB2 OQQ |
UK |
|||
Pittsburgh |
PA |
15232 |
USA |